Myovant

Hamilton
Bermuda
United Kingdom

Show jobs for this employer

About Myovant

Myovant Sciences is focused on innovative treatments for women's health conditions and prostate cancer. The company's lead program is relugolix, a phase 3 drug candidate for multiple indications, including uterine fibroids, endometriosis and prostate cancer. Myovant was formed through a strategic partnership between Roivant Sciences and Takeda.
YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Lynn Seely
CFO: Frank Karbe
JOBS:
Please click here for Myovant Sciences job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.

35 articles with Myovant